New MG Cell Model May Best Capture How Autoantibodies Affect Muscles in MG
Cell models that best mirror the surface of muscle cells crowded with acetylcholine receptors (AChR) are most helpful for understanding…
Articles by Ana Pena, PhD
Immunoglobulin Helps by How It Acts on Regulatory T-Cells, Study Finds
Intravenous immunoglobulin (IVIg) works to treat people with myasthenia gravis (MG) by increasing the numbers of regulatory immune cells that…
Levels of Certain B- and T-cells Linked to Ocular MG Turning Generalized
Low blood levels of regulatory immune cells that prevent autoimmune responses, and high levels of antibody-producing memory B-cells may cause …
Osteopontin Protein May Worsen MG by Affecting Immune Cells, Study Finds
The protein osteopontin, thought to be involved in autoimmunity and inflammation, appears to aggravate myasthenia gravis (MG)…
Fewer Plasma Exchange Treatments, Poorer Kidney Health Increase Risk for MG Relapses, Study Suggests
Receiving fewer plasma exchange, or plasmapheresis treatments and having poorer kidney function with lower…
Side Effects of MG Medications Highlight Need for More Tolerable Treatment Options, Study Suggests
Treatments conventionally used for myasthenia gravis (MG) can produce side effects that negatively impact the daily lives of…
Certain Antibodies Increase Risk of Ocular MG Progressing to Generalized Disease, Study Finds
In people with ocular myasthenia gravis, the presence of anti-AChR or anti-MuSK antibodies likely increases their risk of disease…
Late-onset MG Found Primarily in Men, Responds Well to Prednisone With Azathioprine, Study Finds
Most patients with late-onset myasthenia gravis (LOMG) — those whose disease appears at age 50 or later and is…
MG Complicated by Thymus Tumor and Immunodeficiency Should be Treated with Caution, Case Report Warns
A rare case of myasthenia gravis (MG) complicated by a tumor in the thymus and an immunodeficiency known…
Amneal Partners with Kashiv BioSciences to Develop Extended-Release Pyridostigmine for MG Treatment
Amneal has signed a licensing agreement with Kashiv BioSciences to develop and potentially commercialize K127, an extended-release tablet of…